ProfileGDS5678 / 1443837_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 27% 29% 29% 31% 29% 25% 32% 29% 29% 29% 29% 30% 28% 38% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6584727
GSM967853U87-EV human glioblastoma xenograft - Control 22.6632229
GSM967854U87-EV human glioblastoma xenograft - Control 32.6540429
GSM967855U87-EV human glioblastoma xenograft - Control 42.6596231
GSM967856U87-EV human glioblastoma xenograft - Control 52.6049629
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6539725
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.7894832
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.655729
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.6286729
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.6463829
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.6497229
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.6520630
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.6356428
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.8575938